Vivoryon Therapeutics N.V.
· ISIN: NL00150002Q7
· EQS - Company News
Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Corporate News Vivoryon Therapeutics N.V.
In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
This might be interesting for you as well
28 November 2022 01:30PM
Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)
Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)
An update on dose selection and interim blinded safety results from varoglutamstat´s Phase 2b study (VIVIAD) will be presented
Halle (Saale) / Munich, Germany, November 28, 2022 ...
Vivoryon Therapeutics N.V.
28 November 2022 01:30PM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)
Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)
An update on dose selection and interim blinded safety results from varoglutamstat´s Phase 2b study (VIVIAD) will be presented
Halle (Saale) / Munich, Germany, November 28, 2022 ...
Vivoryon Therapeutics N.V.
23 November 2022 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares
Listing of additional shares completed after private placement realizing the investment of EUR 15 million in the ...
Vivoryon Therapeutics N.V.
23 November 2022 07:00AM
Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares
Listing of additional shares completed after private placement realizing the investment of EUR 15 million in the ...
Vivoryon Therapeutics N.V.
22 November 2022 07:20AM
Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
HALLE (SAALE) / MUNICH, GERMANY, November 22, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modula...
Vivoryon Therapeutics N.V.
22 November 2022 07:20AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
HALLE (SAALE) / MUNICH, GERMANY, November 22, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modula...
Vivoryon Therapeutics N.V.
14 November 2022 07:00AM
Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022
Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022
HALLE (SAALE) / MUNICH, GERMANY, November 14, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to m...
Vivoryon Therapeutics N.V.
14 November 2022 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022
Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022
HALLE (SAALE) / MUNICH, GERMANY, November 14, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to m...
Vivoryon Therapeutics N.V.
30 September 2022 08:47AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress
Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress
HALLE (SAALE) / MUNICH, GERMANY, September 30, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the ...
Vivoryon Therapeutics N.V.
30 September 2022 08:47AM
Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress
Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress
HALLE (SAALE) / MUNICH, GERMANY, September 30, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the ...
Vivoryon Therapeutics N.V.
30 September 2022 08:45AM
Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
Vivoryon Therapeutics AnnouncesSuccessful Private Placement of up to EUR 30 Million
Significant commitment from longstanding investor Claus Christiansen and new investor Dawn Biopharma (a...
Vivoryon Therapeutics N.V.
30 September 2022 08:45AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
Vivoryon Therapeutics AnnouncesSuccessful Private Placement of up to EUR 30 Million
Significant commitment from longstanding investor Claus Christiansen and new investor Dawn Biopharma (a...
Vivoryon Therapeutics N.V.
26 September 2022 07:00AM
Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
HALLE (SAALE) / MUNICH, GERMANY, September 26, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to mod...
Vivoryon Therapeutics N.V.
26 September 2022 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
HALLE (SAALE) / MUNICH, GERMANY, September 26, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to mod...
Vivoryon Therapeutics N.V.
31 July 2022 06:05PM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
Data underscore the unique potential of Vivoryon’s N3pE-focused strategy in mono- and combination therapy settings in AD
Combination treatment of aducanumab and varoglutamstat achieves additive effect on Abeta p...
Vivoryon Therapeutics N.V.
31 July 2022 06:05PM
Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
Data underscore the unique potential of Vivoryon’s N3pE-focused strategy in mono- and combination therapy settings in AD
Combination treatment of aducanumab and varoglutamstat achieves additive effect on Abeta p...
Vivoryon Therapeutics N.V.
31 July 2022 06:00PM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique Opportunity in AD
Safety data from 181 patients show no on-target toxicity and no clinical signs of ARIA
Therapeutic dose of 600 mg varoglutamstat given twice daily sele...
Vivoryon Therapeutics N.V.
31 July 2022 06:00PM
Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique Opportunity in AD
Safety data from 181 patients show no on-target toxicity and no clinical signs of ARIA
Therapeutic dose of 600 mg varoglutamstat given twice daily sele...
Vivoryon Therapeutics N.V.
23 June 2022 07:00AM
Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD
Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD
- Parallel group, dose-finding part of the study completed
- DSMB recommends that the study should proceed with a maximum dose of 600 mg BID varoglutamstat or placebo
- All subjects randomized to the trea...
Vivoryon Therapeutics N.V.
22 June 2022 07:13PM
Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022
Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022
- All proposed resolutions approved
- All existing members re-appointed
- Board strengthened and diversified
HALLE (SAALE) / MUNICH, GERMANY, June 22, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused...
Vivoryon Therapeutics N.V.
15 June 2022 07:00AM
Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress
Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress
HALLE (SAALE) / MUNICH, GERMANY, June 15, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and...
Vivoryon Therapeutics N.V.
08 June 2022 07:00AM
Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022
Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022
Halle (Saale) / Munich, Germany, June 08, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stabilit...
Vivoryon Therapeutics N.V.
11 May 2022 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022
Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022
Halle (Saale) / Munich, Germany, May 11, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon; or the Company), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stabilit...
Vivoryon Therapeutics N.V.
28 April 2022 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress
Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress
Substantial progress in clinical development of QPCT/L inhibitor varoglutamstat, EU and U.S. clinical studies in AD on track
FDA Fast Track designation for lead product candidate in AD
Partnered clinical development of varoglutamstat in Chi...
Vivoryon Therapeutics N.V.
21 April 2022 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022
Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022
Halle (Saale) / Munich, Germany, April 21, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate th...
Vivoryon Therapeutics N.V.
20 April 2022 12:01PM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences
Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences
HALLE (SAALE) / MUNICH, GERMANY, April 20, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologic...
Vivoryon Therapeutics N.V.
01 April 2022 08:47AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 21 Million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 21 Million
Halle (Saale) / Munich, Germany, April 1, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00...
Vivoryon Therapeutics N.V.
31 March 2022 05:45PM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement
Halle (Saale) / Munich, Germany, March 31, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
Vivoryon Therapeutics N.V.
07 March 2022 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
HALLE (SAALE) / MUNICH, GERMANY, March 7, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically...
Vivoryon Therapeutics N.V.
28 February 2022 01:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease
Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease
Halle (Saale) / Munich, Germany and Nanjing, China, February 28, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnolog...
Vivoryon Therapeutics N.V.
04 January 2022 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
HALLE (SAALE) / MUNICH, GERMANY, January 4, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of patholo...
Vivoryon Therapeutics N.V.
22 December 2021 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
Halle (Saale) / Munich, Germany December 22, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the act...
Vivoryon Therapeutics N.V.
04 November 2021 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q3 2021 Financial Results and Highlights Operational Progress
Vivoryon Therapeutics N.V. Reports Q3 2021 Financial Results
and Highlights Operational Progress
HALLE (SAALE) / MUNICH, GERMANY, November 4, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity ...
Vivoryon Therapeutics N.V.
01 November 2021 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Third Quarter 2021 Financial Results on November 4, 2021
Vivoryon Therapeutics N.V. to Report Third Quarter 2021 Financial Results on November 4, 2021
Halle (Saale) / Munich, Germany, November 1, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and st...
Vivoryon Therapeutics N.V.
18 October 2021 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer's Disease
Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer's Disease
This announcement contains Inside Information as defined under the Market Abuse Regulation (EU) No. 596/2014
VIVIAD Phase 2b study in Europe on track for interim safety readout in mid-2022
VIVA-MIND Phase 2 study in t...
Vivoryon Therapeutics N.V.
21 September 2021 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress
Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress
Strategic regional licensing partnership with Simcere Pharmaceutical Group to treat AD in Greater China
US Phase 2 VIVA-MIND study for varoglutamstat in AD initiated as planned
Conference call and webcast scheduled for September 21, 2021 at 3:00 pm CEST / 9:...
Vivoryon Therapeutics N.V.
14 September 2021 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Publish its Financial Results for H1 2021 and Operational Progress
Vivoryon Therapeutics N.V. to Publish its Financial Results for H1 2021
and Operational Progress
Halle (Saale) / Munich, Germany, September 14, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity a...
Vivoryon Therapeutics N.V.
09 September 2021 04:41PM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Halle (Saale) / Munich, Germany, September 9, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stabi...
Vivoryon Therapeutics N.V.
29 June 2021 01:11AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance
Vivoryon Therapeutics Provides Update on Financial Guidance
Halle (Saale) / Munich, Germany, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines, today announced an update on its financial guidance. Acco...
Vivoryon Therapeutics N.V.
29 June 2021 01:03AM
Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer's Disease in Greater China
Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer's Disease in Greater China
Halle (Saale)/Munich, Germany and Nanjing, China, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-st...
Vivoryon Therapeutics N.V.
28 June 2021 06:00PM
Vivoryon Therapeutics N.V.: Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.
Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.
HALLE (SAALE) / MUNICH, GERMANY, June 28, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines today announced, that its shareholders app...
Vivoryon Therapeutics N.V.
25 June 2021 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Financial Results for the First Quarter of 2021 and Provides Corporate Update
Vivoryon Therapeutics Announces Financial Results
for the First Quarter of 2021 and Provides Corporate Update
HALLE (SAALE) / MUNICH, GERMANY, June 25, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) today announced financial results and provided a corporate update for the first quarter of 2021, ending March...
Vivoryon Therapeutics N.V.
31 May 2021 06:00PM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Reschedules Reporting of 1st Quarter 2021 and Provides Update for Annual General Meeting of Shareholders
Vivoryon Therapeutics Reschedules Reporting of 1st Quarter 2021 and Provides Update for Annual General Meeting of Shareholders
HALLE (SAALE) / MUNICH, GERMANY, May 31, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) announced today that the publication of the 1st quarter 2021 financial results, which had...
Vivoryon Therapeutics N.V.
17 May 2021 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Notice of its Annual General Meeting of Shareholders to be Held on June 28, 2021
Vivoryon Therapeutics Announces Notice of its Annual General Meeting of Shareholders to be Held on June 28, 2021
HALLE (SAALE) / MUNICH, GERMANY, May 17, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) invites all shareholders to Vivoryon's annual general meeting of shareholders to be held on Monday, June 28...
Vivoryon Therapeutics N.V.
30 April 2021 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2020 Financial Results
Vivoryon Therapeutics N.V. Reports Full Year 2020 Financial Results
English conference call and webcast today, April 30th at 3:00 pm CEST (09:00 am EDT)
HALLE (SAALE) / MUNICH, GERMANY, April 30, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) today announced its financial results for the twelve month p...
Vivoryon Therapeutics N.V.
14 April 2021 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reschedules the Reporting of the Full Year 2020 Financial Results to April 30, 2021
Vivoryon Therapeutics N.V. Reschedules the Reporting of the Full Year 2020 Financial Results to April 30, 2021
HALLE (SAALE) / MUNICH, GERMANY, 14 April 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) announced today that the publication of the Full Year 2020 financial results, which had been scheduled for April 20th, 202...
Vivoryon Therapeutics N.V.
01 April 2021 07:00AM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Host Virtual Event on Current Clinical Landscape in Alzheimer's Disease Treatment Options with Leaders and Experts on April 15th, 2021
Vivoryon Therapeutics to Host Virtual Event on Current Clinical Landscape in Alzheimer's Disease Treatment Options with Leaders and Experts on April 15th, 2021
HALLE (SAALE) / MUNICH, GERMANY, 1 April 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) announced today that it will host a virtual event covering n...
Vivoryon Therapeutics N.V.
More Vivoryon Therapeutics N.V. related information
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Corporate Research | 0 | - | - | Corporate Research |
| Directors Dealings | 0 | - | - | DD |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.
v.07062023 EN